Core Insights - PTC has announced the acquisition of IncQuery Group, which specializes in application lifecycle management (ALM) and systems engineering consultancy services for global manufacturers and product companies [1][2] - The acquisition aims to enhance PTC's capabilities in ALM, systems engineering, and product lifecycle management (PLM), thereby improving support for customers in these areas [1][2] Company Overview - PTC is a global software company headquartered in Boston, Massachusetts, employing over 7,000 people and serving more than 30,000 customers worldwide [3] - The company focuses on enabling manufacturers and product companies to digitally transform their design, manufacturing, and service processes for physical products [3] Strategic Importance - The acquisition is positioned as a strategic move to accelerate PTC's ALM and PLM portfolio integrations, addressing customer needs for faster and higher-quality product development while meeting regulatory and sustainability requirements [2] - Both PTC and IncQuery Group share a commitment to transforming digital engineering and product development processes, which is expected to enhance PTC's engineering and product development portfolio [2]

Core Insights - PTC Inc. has launched Codebeamer 3.0, an advanced Application Lifecycle Management (ALM) solution designed to enhance product development, sustainability, quality, and regulatory compliance [1][4]. Product Features - Codebeamer 3.0 introduces a modern branching method and scaled working sets to improve collaboration among engineering teams, enabling faster development by reusing product requirements and test cases [2]. - The new version includes a Sustainability Template to support eco-friendly product development, reducing reliance on physical prototypes and promoting sustainable design practices [3]. - For industries with stringent regulatory requirements, Codebeamer 3.0 provides full traceability across products, aiding in quality assurance and compliance [3]. Strategic Collaborations - PTC has formed strategic collaborations, including a partnership with Microsoft and Volkswagen Group to develop Codebeamer Copilot, an AI-powered tool aimed at streamlining software development processes for physical products [4]. - In September 2024, PTC signed a strategic collaboration agreement with Amazon Web Services to enhance its Onshape solution, focusing on improving features and advancing AI efforts [7]. Financial Outlook - PTC has narrowed its sales outlook for 2025 to a range of $2,430 million to $2,530 million, down from the previous projection of $2,505 million to $2,605 million, due to forex volatility and a challenging sales environment [8]. Market Performance - PTC currently holds a Zacks Rank of 3 (Hold), with its shares declining by 15.4% over the past year, compared to a 4% decline in the Zacks Computer-Software industry [9].

WARREN, N.J., March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to not renew the authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy. While this action effectively removes the drug's conditional marketing authorization in the European Economic Area, the EC indicat ...

Industry-leading ALM solution delivers enhanced speed and scalability with variant management Modern branching method and scaled working sets enable customers to accelerate development of products and ensure compliance Sustainability Template offers eco-friendly design best practices and reduces physical prototypes through reuse Provides end-to-end traceability and process support for product compliance in regulated industries BOSTON, March 27, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced the rel ...

PTC Inc (PTC) is set to exhibit its latest innovation, Windchill AI, at Hannover Messe 2025, strengthening its position in AI-powered product lifecycle management (PLM). Windchill AI is an AI-powered assistant that leverages the vast amount of product data stored in Windchill, PTC’s flagship PLM solution. This advanced AI tool enables engineers and designers to access information faster, streamline decision-making and improve product development efficiency. In addition to Windchill AI, PTC will exhibit its ...

PTC to preview Windchill AI and Document Vault AI agent PTC to demonstrate agentic AI across the product digital thread with Windchill AI, Codebeamer AI, and ServiceMax AI PTC demonstrations available in Hall 17, Stand D40 from March 31 – April 4, 2025 BOSTON, March 25, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) will preview its Windchill® AI product lifecycle management (PLM) assistant, a generative AI-powered PLM offering, at Hannover Messe 2025. Windchill AI leverages all product data stored in Windchill to ...

BOSTON, March 13, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it has appointed Trac Pham to its Board of Directors, effective March 17, 2025.Pham is the former Chief Financial Officer of Synopsys, a recognized leader in electronic design automation and semiconductor development. During his tenure as CFO, Pham led Synopsys through two significant transformations that helped scale the company from $2.0B to $5.1B in revenue while expanding operating margins. He is currently on the Board of Dire ...

Group 1 - PTC Therapeutics is facing declining revenues and profitability but is preparing for a turnaround [1] - The company has potential asymmetric upside due to several regulatory catalysts expected in 2025, including the FDA review of vatiquinone for Friedreich's ataxia and sepiapterin [1]

Core Viewpoint - PTC Inc. has reported a mixed performance in its recent earnings, with a notable earnings beat but a decline in share price, raising questions about future performance leading up to the next earnings release [1][2]. Financial Performance - PTC reported Q1 fiscal 2025 non-GAAP EPS of $1.10, exceeding the Zacks Consensus Estimate by 20.9% [2]. - Revenues reached $565 million, reflecting a 3% year-over-year increase, and beating the consensus estimate by 2.4% [3]. - Recurring revenues were $524.3 million, up 3.6% year over year, while perpetual licenses increased by 11.4% to $9.4 million [5]. - License revenues constituted 30.6% of total revenues at $172.8 million, down 6.1% from the previous year, while support and cloud services revenues increased by 9.2% to $361 million [6]. - Professional services revenues decreased by 12.1% year over year to $31.4 million [7]. - PLM revenues were $353 million, up 1% year over year, and CAD revenues were $212 million, up 5% year over year [8]. Annualized Recurring Revenue (ARR) - ARR was reported at $2.205 billion, a 7% increase year over year, with constant currency ARR at $2.277 billion, up 11% year over year [9]. - PLM and CAD ARR were $1,357 million and $848 million, rising 8% and 5% year over year, respectively [9]. Operating Metrics - Non-GAAP gross margin remained stable at 82.7% year over year [10]. - Total operating expenses increased by $17 million year over year to $338 million, while operating income fell by 4% year over year to $191 million [10]. - Operating margin on a non-GAAP basis improved by 240 basis points year over year to 34% [11]. Balance Sheet and Cash Flow - As of December 31, 2024, cash and cash equivalents were $196 million, down from $266 million as of September 30, 2024 [12]. - Total debt decreased to $1.544 billion from $1.748 billion [12]. - Cash provided by operating activities was $238 million, compared to $187 million in the prior year, and free cash flow was $236 million, up from $183 million [12]. Financial Outlook - For Q2 fiscal 2025, PTC estimates revenues between $590 million and $620 million, with non-GAAP EPS projected in the range of $1.30 to $1.50 [13]. - Full-year fiscal 2025 revenue projections are now between $2,430 million and $2,530 million, indicating a 6-10% year-over-year increase [14]. - Non-GAAP EPS for fiscal 2025 is estimated to be between $5.30 and $6.00, suggesting a 4-18% increase [14]. - Cash from operations is projected to be between $850 million and $865 million, indicating a 13% to 15% year-over-year increase [15]. Market Sentiment - Estimates for PTC have trended downward recently, with a consensus estimate shift of -8.27% [16]. - PTC holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [18].

Company Announcements - PTC Therapeutics, Inc. will participate in fireside chats at two upcoming investor conferences: TD Cowen 45th Annual Health Care 2025 Conference on March 4 at 11:10 a.m. ET and Barclays 27th Annual Global Healthcare Conference on March 11 at 12:30 p.m. ET [1] - The presentations will be available for live webcast on PTC's website and will be archived for 30 days after the event [1] Company Overview - PTC Therapeutics is a global biopharmaceutical company focused on discovering, developing, and commercializing clinically differentiated medicines for rare disorders [2] - The company's innovation in identifying new therapies and its ability to globally commercialize products are key drivers of its investment in a diverse pipeline of transformative medicines [2]